This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Diabetes Treatment With Glucobay in Combination With Metformin

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01612741
First received: June 4, 2012
Last updated: July 7, 2014
Last verified: July 2014
June 4, 2012
July 7, 2014
April 2008
January 2009   (Final data collection date for primary outcome measure)
  • Data collection on body weight [ Time Frame: 16 weeks ]
  • Data collection on blood glucose [ Time Frame: 16 weeks ]
  • Data collection on Hba1c [ Time Frame: 16 weeks ]
  • Data collection on pre treatment concomitant diseases [ Time Frame: 16 weeks ]
Same as current
Complete list of historical versions of study NCT01612741 on ClinicalTrials.gov Archive Site
Safety variables will be summarized using descriptive statistics based on adverse events collection [ Time Frame: 16 weeks ]
Same as current
Not Provided
Not Provided
 
Diabetes Treatment With Glucobay in Combination With Metformin
Prospecitve, Non Interventional, Non Controlled, Post Marketing Survelliance Study to Evaluate Efficacy, Safety, Tolerability of Glucobay on Top of Metformin Under Daily Life Treatment Conditions
In this prospective, non interventional, observational Post Marketing Survelliance study data are obtained on the efficacy, safety and tolerability of Glucobay treatment on top of metformin under daily life treatment conditions.Specifically investigated is the influence of Glucobay on Post Prandial Blood Glucose and HbA1c as well as on pateint's weight when added to an already existing metformin therapy.The study is planned to carried out in 25000 - 30000 patients from 200 trial sites in India.The PMS study will be performed with commercially available medication prescribed within regular practice of the physician. No other examination will be performed than would be done without Post Marketing Survelliance study.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Type 2 diabetes
Type 2 Diabetes Mellitus
Drug: Acarbose (Precose/Glucobay, BAYG5421)
Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
Group 1
Intervention: Drug: Acarbose (Precose/Glucobay, BAYG5421)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
19509
January 2009
January 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patient with type 2 diabetes with one of the following treatment ongoing : 1) Metformin 2) Metformin + OHA.
  • In such patients, if investigator feels that addition of acarbose would be benficial for the patients

Exclusion Criteria:

  • According to local product information
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
India
 
 
NCT01612741
13925
GB0711IN ( Other Identifier: company internal )
No
Not Provided
Not Provided
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP